ZBTB32 and neoplasm: The expression of ZBTB32 and CCL5 was also determined by western blot analysis using tumor masses, and the mutation of di‐methylated Lys148 inhibited ZBTB32 and CCL5 expression (Figure 7K,L), which was consistent with the results in A549 and H460 cells.